Skip to content

Member Spotlight: Valeria Santini, MD
Phase 1b trial reports promising outcomes with olverembatinib plus blinatumomab in relapsed or refractory CML or ALL
SOHO 2026 posters not to miss: MPN edition with Dr. Gabriela Hobbs
Young investigators define the SOHO difference
Dr. Jerald Radich highlights meaningful posters in CML at SOHO 2026

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates/Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

$Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML$

Cellular Therapy

$Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML$

Leukemia

$Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML$

Lymphoma

$Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML$

Multiple Myeloma

$Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML$

Myelodysplastic Syndromes

$Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML$

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

September 21, 2026

Insider Podcast
Society Updates/Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Leukemia Acute Myeloid Leukemia

Acute Myeloid Leukemia

Discontinuation

Acute Myeloid Leukemia

Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML

by SOHO Insider Editors
August 1, 2025
0 Comments

cancer cells

Acute Myeloid Leukemia Myelodysplastic Syndromes News

Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML

by SOHO Insider Editors
July 22, 2025
0 Comments

Leukemia Acute Myeloid Leukemia News

Pathways & Perspectives with Alice Mims, MD

by SOHO Insider Editors
July 16, 2025
0 Comments

Leukemia Acute Myeloid Leukemia News SOHO Insider Podcast

Inside AML challenges with Drs. Jabbour, Daver

by Leah Sherwood
June 25, 2025
0 Comments

Immunotherapy.

Leukemia Acute Myeloid Leukemia

New immunotherapy approach may treat aggressive AML, MDS

by SOHO Insider Editors
June 6, 2025
0 Comments

Acute,Myeloid,Leukemia,(aml),Cells,In,Blood,Flow,-,Closeup

Leukemia Acute Myeloid Leukemia

Triplet combination does not extend survival for patients with AML

by SOHO Insider Editors
May 12, 2025
0 Comments

Leukemia cells and red blood cells

Leukemia Acute Myeloid Leukemia News

Triplet ‘effective’ in relapsed or refractory AML

by SOHO Insider Editors
April 23, 2025
0 Comments

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Leukemia Acute Myeloid Leukemia News

No benefit to adding pevonedistat to SOC for patients with newly diagnosed AML

by Leah Sherwood
March 27, 2025
0 Comments

Acute,Myeloid,Leukemia,(aml),Cells,In,Blood,Flow,-,Closeup

Leukemia Acute Myeloid Leukemia News

Olutasidenib plus azacitidine show ‘durable’ responses in relapsed or refractory IDH1-mutated AML

by Leah Sherwood
March 11, 2025
0 Comments

Leukemia Acute Myeloid Leukemia News

Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML

by Leah Sherwood
March 6, 2025
0 Comments

1
...
3
4
5
6

Top Categories

Cellular Therapy

82

Leukemia

134

Lymphoma

141

Multiple Myeloma

120

Myelodysplastic Syndromes

49

Myeloproliferative Neoplasms

36

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML

Cellular Therapy

Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML

Leukemia

Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML

Lymphoma

Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML

Multiple Myeloma

Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML

Myelodysplastic Syndromes

Lintuzumab-Ac225 plus CLAG-M shows promising efficacy in R/R AML

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Member Spotlight: Valeria Santini, MD

Phase 1b trial reports promising outcomes with olverembatinib plus blinatumomab in relapsed or refractory CML or ALL

SOHO 2026 posters not to miss: MPN edition with Dr. Gabriela Hobbs

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.